BACKGROUND: Hemodialyzers should efficiently eliminate small and middle molecular uremic toxins and possess exceptional hemocompatibility to improve well-being of patients with end-stage kidney disease. However, performance and hemocompatibility get compromised during treatment due to adsorption of plasma proteins to the dialyzer membrane. Increased membrane hydrophilicity reduces protein adsorption to the membrane and was implemented in the novel FX CorAL dialyzer. The present randomized controlled trial compares performance and hemocompatibility profiles of the FX CorAL dialyzer to other commonly used dialyzers applied in hemodiafiltration treatments. METHODS: This prospective, open, controlled, multicentric, interventional, crossover study randomized stable patients on post-dilution online hemodiafiltration (HDF) to FX CorAL 600, FX CorDiax 600 (both Fresenius Medical Care) and xevonta Hi 15 (B. Braun) each for 4 weeks. Primary outcome was β2-microglobulin removal rate (β2-m RR). Non-inferiority and superiority of FX CorAL versus comparators were tested. Secondary endpoints were RR and/or clearance of small and middle molecules, and intra- and interdialytic profiles of hemocompatibility markers, with regards to complement activation, cell activation/inflammation, platelet activation and oxidative stress. Further endpoints were patient reported outcomes (PROs) and clinical safety. RESULTS: 82 patients were included and 76 analyzed as intention-to-treat (ITT) population. FX CorAL showed the highest β2-m RR (76.28%), followed by FX CorDiax (75.69%) and xevonta (74.48%). Non-inferiority to both comparators and superiority to xevonta were statistically significant. Secondary endpoints related to middle molecules corroborated these results; performance for small molecules was comparable between dialyzers. Regarding intradialytic hemocompatibility, FX CorAL showed lower complement, white blood cell, and platelet activation. There were no differences in interdialytic hemocompatibility, PROs, or clinical safety. CONCLUSIONS: The novel FX CorAL with increased membrane hydrophilicity showed strong performance and a favorable hemocompatibility profile as compared to other commonly used dialyzers in clinical practice. Further long-term investigations should examine whether the benefits of FX CorAL will translate into improved cardiovascular and mortality endpoints. TRIAL REGISTRATION: eMPORA III registration on 19/01/2021 at ClinicalTrials.gov (NCT04714281).
- MeSH
- beta-2-mikroglobulin krev MeSH
- chronické selhání ledvin terapie MeSH
- hemodiafiltrace * přístrojové vybavení metody MeSH
- hydrofobní a hydrofilní interakce * MeSH
- klinické křížové studie * MeSH
- lidé středního věku MeSH
- lidé MeSH
- membrány umělé * MeSH
- prospektivní studie MeSH
- senioři MeSH
- Check Tag
- lidé středního věku MeSH
- lidé MeSH
- mužské pohlaví MeSH
- senioři MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- multicentrická studie MeSH
- randomizované kontrolované studie MeSH
Tento článek shrnuje poznatky v oboru nefrologie za poslední rok. Studie EMPA ‐KIDNEY potvrdila výrazný renoprotektivní efekt SGLT‐2 inhibitorů u nemocných bez diabetu, zatímco renoprotektivní efekt u nemocných s diabetem byl potvrzen u finerenonu. Studie STOP ‐ACEi ukázala, že přerušování léčby inhibitory systému renin‐angiotesin‐aldosteron nemá smysl u pokročilého chronického onemocnění ledvin. Studie CHAP prokázala významný efekt včasné léčby krevního tlaku při jeho vzestupu nad 140/90 mm Hg u těhotných žen. Dále bylo potvrzeno, že jak systémová, tak topická kortikoterapie představuje možnosti léčby IgA nefropatie. Rovněž ve studii CONVINCE bylo prokázáno, že hemodiafiltrace má mortalitní benefity oproti hemodialýze. Studií NOSTONE byla zpochybněna role thiazidových diuretik v prevenci urolitiázy. Potenciálně zásadní novinkou pro vysoce senzitizované pacienty čekající na transplantaci ledviny představuje IgG ‐degradující enzym Streptococcus pyogenes – imlifidáza. Tyto nové poznatky dávají pacientům naději na zpomalení progrese chronického onemocnění ledvin a rovněž zlepšují jejich vyhlídky v případě nutnosti zahájení náhrady funkce ledvin.
This article summarizes the latest developments in the field of nephrology over the past year. The EMPA-KIDNEY study confirmed a significant renoprotective effect of SGLT-2 inhibitors in patients without diabetes, while a renoprotective effect in patients with diabetes was confirmed for finerenone. The STOP-ACEi study showed that discontinuation of renin-angiotensin-aldosterone system inhibitors does not confer benefit in patients with advanced chronic kidney disease. The CHAP study showed a significant beneficial effect of early treatment of hypertension above 140/90mmHg in pregnant women. It has also been confirmed that both systemic and topical corticosteroids represent viable treatment options for IgA nephropathy. Furthermore, the CONVINCE study showed that hemodiafiltration has mortality benefits over hemodialysis. The role of thiazide diuretics in the prevention of urolithiasis has been questioned by the NOSTONE study. The IgG-degrading enzyme of Streptococcus pyogenes - imlifidase - is a potentially crucial innovation for highly sensitized patients awaiting kidney transplantation. These new findings give patients hope for slowing the progression of chronic kidney disease and also improves their prospects if the need for renal replacement therapy arises.
- MeSH
- albuminurie epidemiologie MeSH
- diabetes mellitus * MeSH
- diabetické nefropatie komplikace terapie MeSH
- dialýza ledvin statistika a číselné údaje MeSH
- hemodiafiltrace statistika a číselné údaje MeSH
- hodnoty glomerulární filtrace MeSH
- komplikace diabetu terapie MeSH
- lidé MeSH
- registrace * MeSH
- statistika jako téma MeSH
- Check Tag
- lidé MeSH
- MeSH
- arteriovenózní zkrat MeSH
- cévní přístupy MeSH
- hemodiafiltrace * metody MeSH
- lidé MeSH
- Check Tag
- lidé MeSH
Hemodiafiltration (HDF) adds convective elimination of middle molecules (MM), proportional to filtered volume (Vconv) on the top of diffusion-based elimination of small molecules (SM) by conventional hemodialysis (HD). Studies, both observational and randomized controlled ones, performed so far generally indicated positive impact of higher Vconv on all-cause mortality in HDF patients, although the magnitude of Vconv at which HDF becomes apparently superior to HD differed widely among the studies. Also the issue of a suitable anthropometric parameter by which the Vconv should be normalized has not yet been solved. Data from the ESHOL study seems to indicate that patient´s body surface area (BSA) could well be used for this—mortality was decreasing with increasing Vconv/BSA with a bottom plateau starting at about 15 L/m2 . We have therefore devised a formula and a graph for determination of Vconv which fulfils the requirement Vconv/BSA = 15. Assuming maximum feasible and safe filtration fraction QF/QB = 0.3, the Vconv actually defines the necessary blood flow (QB) to reach Vconv/BSA = 15 as QB = 15·BSA/(0.3·t) (t – session time). It is also possible to check what QB is needed in terms of sufficient diffusion-based transport (target Kt/V) and compare both QB values to see if adequate combined elimination of both SM and MM can be achieved at the same time and under what conditions, respectively.
- Klíčová slova
- vazače fosfátů,
- MeSH
- chelátory farmakologie terapeutické užití MeSH
- chronické selhání ledvin * komplikace patofyziologie MeSH
- dialýza ledvin metody MeSH
- fibroblastové růstové faktory fyziologie MeSH
- fosfáty antagonisté a inhibitory metabolismus škodlivé účinky MeSH
- fosfor dietní aplikace a dávkování škodlivé účinky MeSH
- hemodiafiltrace metody MeSH
- hyperfosfatemie * etiologie farmakoterapie terapie MeSH
- hyperparatyreóza etiologie komplikace patofyziologie MeSH
- lanthan farmakologie škodlivé účinky terapeutické užití MeSH
- lidé MeSH
- sacharosa analogy a deriváty MeSH
- sevelamer farmakologie škodlivé účinky terapeutické užití MeSH
- sloučeniny hliníku škodlivé účinky MeSH
- sloučeniny vápníku škodlivé účinky terapeutické užití MeSH
- sloučeniny železa farmakologie terapeutické užití MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- práce podpořená grantem MeSH
BACKGROUND: Low bone mineral density (BMD) and trabecular bone score (TBS) are established risk factors for fractures even in hemodialysis population and they seem to be significantly lower in comparison with general population. The aim of our study was to describe 2-year loss of BMD and TBS and their predictors in hemodialysis patients. METHODS: From 59 non-selected patients (mean age 67.6 ± 13.1 years) from one dialysis centre, treated with hemodiafiltration (HDF), clinical and laboratory characteristics were obtained and densitometry examinations (with BMD and TBS results) were performed initially and at the end of 2-year follow-up. RESULTS: Two-year decrease in BMD of lumbar spine reached 4.1% (ns), of proximal femur 9.1% (p = 0.004), and of femoral neck 1.3% (ns). In the co-educated cohort, BMD decrease in all the sites correlated significantly with age and only the change of BMD of lumbar spine was negatively associated with serum calcium (r = - 0.39; p = 0.04) and dialysis vintage (r = - 0.387; p = 0.062), no other predictors of BMD loss were identified. Some predictors of BMD loss were identified with regard to gender. TBS decrease was 0.05 (3.9%; p = 0.03), and similarly, it was not predicted by any of selected parameters. No differences in BMD changes or TBS were observed between the patients with and without fractures. CONCLUSIONS: In patients with HDF, significant BMD and TBS annual losses were observed, and they were associated only with age and (in BMD of lumbar spine) with serum calcium and dialysis vintage.
- MeSH
- absorpční fotometrie MeSH
- bederní obratle diagnostické zobrazování patofyziologie MeSH
- chronické selhání ledvin komplikace patofyziologie terapie MeSH
- dospělí MeSH
- hemodiafiltrace MeSH
- kostní denzita * MeSH
- krček femuru diagnostické zobrazování patofyziologie MeSH
- lidé středního věku MeSH
- lidé MeSH
- následné studie MeSH
- osteoporotické fraktury etiologie MeSH
- osteoporóza komplikace diagnostické zobrazování patofyziologie MeSH
- prospektivní studie MeSH
- rizikové faktory MeSH
- senioři nad 80 let MeSH
- senioři MeSH
- sexuální faktory MeSH
- trabekulární kostní tkáň patofyziologie MeSH
- vápník krev MeSH
- věkové faktory MeSH
- Check Tag
- dospělí MeSH
- lidé středního věku MeSH
- lidé MeSH
- mužské pohlaví MeSH
- senioři nad 80 let MeSH
- senioři MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
BACKGROUND: Hypertension and cardiovascular disease are common in children undergoing dialysis. Studies suggest that hemodiafiltration (HDF) may reduce cardiovascular mortality in adults, but data for children are scarce. METHODS: The HDF, Heart and Height study is a nonrandomized observational study comparing outcomes on conventional hemodialysis (HD) versus postdilution online HDF in children. Primary outcome measures were annualized changes in carotid intima-media thickness (cIMT) SD score and height SD score. RESULTS: We enrolled 190 children from 28 centers; 78 on HD and 55 on HDF completed 1-year follow-up. The groups were comparable for age, dialysis vintage, access type, dialysis frequency, blood flow, and residual renal function. At 1 year, cIMT SD score increased significantly in children on HD but remained static in the HDF cohort. On propensity score analysis, HD was associated with a +0.47 higher annualized cIMT SD score compared with HDF. Height SD score increased in HDF but remained static in HD. Mean arterial pressure SD score increased with HD only. Factors associated with higher cIMT and mean arterial pressure SD-scores were HD group, higher ultrafiltration rate, and higher β2-microglobulin. The HDF cohort had lower β2-microglobulin, parathyroid hormone, and high-sensitivity C-reactive protein at 1 year; fewer headaches, dizziness, or cramps; and shorter postdialysis recovery time. CONCLUSIONS: HDF is associated with a lack of progression in vascular measures versus progression with HD, as well as an increase in height not seen in the HD cohort. Patient-related outcomes improved among children on HDF correlating with improved BP control and clearances. Confirmation through randomized trials is required.
- MeSH
- beta-2-mikroglobulin krev MeSH
- bolesti hlavy etiologie MeSH
- C-reaktivní protein MeSH
- chronické selhání ledvin krev komplikace terapie MeSH
- dialýza ledvin škodlivé účinky MeSH
- dítě MeSH
- fosfáty krev MeSH
- hemodiafiltrace * škodlivé účinky metody MeSH
- hemoglobiny metabolismus MeSH
- hodnocení výsledků péče pacientem MeSH
- hospitalizace MeSH
- hypertenze etiologie MeSH
- intimomediální šíře tepenné stěny * MeSH
- krevní tlak MeSH
- lidé MeSH
- mladiství MeSH
- mladý dospělý MeSH
- parathormon krev MeSH
- předškolní dítě MeSH
- svalové křeče etiologie MeSH
- tělesná výška * MeSH
- závrať etiologie MeSH
- Check Tag
- dítě MeSH
- lidé MeSH
- mladiství MeSH
- mladý dospělý MeSH
- mužské pohlaví MeSH
- předškolní dítě MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- multicentrická studie MeSH
- pozorovací studie MeSH
- srovnávací studie MeSH
PURPOSE: Bone involvement represents one of the complications of end-stage chronic kidney disease, with fractures being its major risk. The aim of our study was to assess the frequency and predictors of low-trauma fractures in a cohort of maintenance hemodialysis patients followed-up on for 2 years. METHODS: 59 patients (67.6 ± 13.1 years, 43 males) treated with hemodiafiltration underwent initially laboratory (markers of calcium-phosphate metabolism and bone turnover markers) and densitometry examination with TBS assessment (Lunar Prodigy, TBS software 2.1.2). During 24-month follow-up, the frequency of low-trauma fractures was assessed and possible predictors of increased fracture risk were identified using product-moment correlation matrices. RESULTS: Altogether 7 (11.9%) low-trauma fractures were observed. In the whole group, age (P = 0.047), T-score in proximal femur (P = 0.04), low vitamin D, low BMI (P = 0.03 for both), and higher FRAX for major osteoporotic fracture (P = 0.01) were connected with fractures, but in multi-variate analysis only BMI remained significantly negatively associated with fractures (P = 0.047). TBS and bone turnover markers failed to predict fractures. However, women with fractures had significantly lower serum phosphate (P = 0.03) and higher parathyroid hormone (P = 0.04). Parameters of hip structure analysis significantly correlated with FRAX, but not with fractures. CONCLUSIONS: In a group of hemodialysis patients from one centre, T-score in proximal femur, low vitamin D, low BMI, and high FRAX for major osteoporotic fracture were associated with low-trauma fractures, however, in multi-variate analysis only low BMI remained a significant predictor of fracture risk.
- MeSH
- acyltransferasy krev MeSH
- chronické selhání ledvin krev terapie MeSH
- fraktury kostí krev epidemiologie MeSH
- hemodiafiltrace MeSH
- index tělesné hmotnosti * MeSH
- kostní denzita MeSH
- lidé středního věku MeSH
- lidé MeSH
- následné studie MeSH
- parathormon krev MeSH
- proteiny z Escherichia coli krev MeSH
- rizikové faktory MeSH
- senioři nad 80 let MeSH
- senioři MeSH
- vitamin D analogy a deriváty krev MeSH
- Check Tag
- lidé středního věku MeSH
- lidé MeSH
- mužské pohlaví MeSH
- senioři nad 80 let MeSH
- senioři MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
